Is low vitamin D status linked to immune and cardiometabolic risk markers?

Low 25-hydroxyvitamin D (25[OH]D) is a credible marker of altered immune and cardiometabolic risk profiles, but these associations do not establish that vitamin D deficiency is their independent cause or that supplementation broadly reverses them.

Immune and cardiometabolic associations

• Lower 25(OH)D is associated with higher inflammatory markers—including C-reactive protein and white-blood-cell counts—and with differences in cytokine and lymphocyte measures. These relationships are heterogeneous and often attenuate after adjustment for adiposity.
• Observational evidence consistently links low status with a less favourable metabolic-risk profile. In one adjusted 5-year cohort, 25(OH)D below 18 ng/mL and 18–23 ng/mL were associated with incident metabolic-syndrome odds of 1.41 and 1.74, respectively, versus ≥34 ng/mL. However, other prospective evidence is null after accounting for BMI and related covariates.

Mechanistic and clinical evidence

• Vitamin-D receptors in innate and adaptive immune cells, plus local conversion to calcitriol, provide biologic plausibility for effects on inflammatory signalling, dendritic-cell phenotype, and T-cell differentiation. Plausible cardiometabolic pathways include renin–angiotensin, insulin, and inflammatory signalling, but these mechanisms have not translated into broad outcome benefits.
• Supplementation effects are context-specific. A 2017 individual-participant meta-analysis found modest acute-respiratory-infection protection with daily/weekly, non-bolus dosing, with a larger effect among those <25 nmol/L; a later larger review did not confirm overall benefit or baseline-status modification.
• Cardiovascular prevention is not supported: 29 randomized trials (>134,000 participants) found no reduction in cardiovascular disease (RR 0.99, 95% CI 0.95–1.03).

Safety and practical implications

• Supplementation increases hypercalcemia (RR 1.54) and hypercalciuria (RR 1.64), supporting indication- and context-specific dosing and monitoring.

Bottom line

• For this 52-year-old man, low vitamin D may signal immune or cardiometabolic risk but is not itself evidence that supplementation will prevent cardiovascular or metabolic disease. Benefit is most defensible when treating confirmed deficiency or a defined clinical indication, rather than using high-dose vitamin D for nonspecific prevention.